Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bermekimab · 1 trial · 3 indications
HiSCR was defined as at least 50 percent (%) reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess count and no increase in draining fistula count relative to baseline.
| Arm | Type | Description |
|---|---|---|
| bermekimab ew | EXPERIMENTAL | 2 800 mg bermekimab loading dose subcutaneous injections, followed by weekly 400 mg bermekimab injections |
| bermekimab eow | EXPERIMENTAL | 2 800 mg loading dose subcutaneous injections, followed by alternating weekly 400 mg bermekimab injections with matching placebo injections |
| placebo ew | PLACEBO_COMPARATOR | 2 800 mg placebo loading dose subcutaneous injections, followed by weekly placebo subcutaneous injections |
| Name | Type | Description |
|---|---|---|
| bermekimab | DRUG | bermekimab 2 mL (200 mg/mL) pre-filled syringe |
| placebo | DRUG | placebo 2 mL pre-filled syringe |
Inclusion Criteria: * Written informed consent provided by the participant * Male or female, age greater than or equal to (\>=) 18 years * Naïve to OR failure of prior targeted biologic therapy for Hidradenitis Suppurativa (HS) (including anti-TNF, anti-IL-17, or JAK inhibitor therapy) * Diagnosis ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
Bermekimab is an investigational small molecule being developed for the treatment of hidradenitis suppurativa, also known as acne inversa. It is intended for patients with this chronic inflammatory skin condition. The drug is currently in clinical development and has not been approved by regulatory authorities.
Bermekimab is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is an investigational small molecule in Phase 2 clinical development for hidradenitis suppurativa.
Bermekimab is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the treatment of hidradenitis suppurativa, a chronic inflammatory skin condition.
Bermekimab has one completed Phase 2 clinical trial, identified as NCT04019041. This study evaluated the efficacy, safety, and tolerability of bermekimab in patients with hidradenitis suppurativa. The trial enrolled 153 participants in the United States and was randomized, double-blind, and placebo-controlled.
Bermekimab is not known to have any alternative names. It is a distinct investigational small molecule being developed by Johnson & Johnson for the treatment of hidradenitis suppurativa. The drug is currently in Phase 2 clinical development.